Pàgina inicial > Resultats de la cerca: Eriksson, Irene
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 2 registres trobats en 0.02 segons.
Articles, 2 registres trobats
Articles 2 registres trobats  
1.
13 p, 1.0 MB Adaptive Pathways : Possible Next Steps for Payers in Preparation for Their Potential Implementation / Vella Bonanno, Patricia (Department of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde) ; Ermisch, Michael (Pharmaceutical Department, National Association of Statutory Health Insurance Funds) ; Godman, Brian (Karolinska Institutet (Estocolm, Suècia). Division of Clinical Pharmacology) ; Martin, Antony P. (Health Economics Centre, University of Liverpool Management School) ; Van Den Bergh, Jesper (Department of Health) ; Bezmelnitsyna, Liudmila (National Research Institution for Public Health) ; Bucsics, Anna (Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA)) ; Arickx, Francis (Department of Pharmaceutical Policy, National Institute for Health and Disability Insurance) ; Bybau, Alexander (Zilveren Kruis Achmea) ; Bochenek, Tomasz (Department of Drug Management, Faculty of Health Sciences, Jagiellonian University Medical College) ; van de Casteele, Marc (Department of Pharmaceutical Policy, National Institute for Health and Disability Insurance) ; Diogène Fadini, Eduard (Hospital Universitari Vall d'Hebron) ; Eriksson, Irene (Karolinska Institutet (Estocolm, Suècia). Department of Medicine Solna) ; Fürst, Jurij (Medicinal Products Department, Health Insurance Institute of Slovenia) ; Gad, Mohamed (Global Health and Development Group, Imperial College) ; Greičiūtė-Kuprijanov, Ieva (Department of Pharmacy, Ministry of Health of the Republic of Lithuania) ; van der Graaff, Martin (National Health Care Institute (ZIN)) ; Gulbinovič, Jolanta (State Medicines Control Agency) ; Jones, Jan (Scottish Medicines Consortium) ; Joppi, Roberta (Clinical Research and Drug Assessment Unit) ; Kalaba, Marija (Pediatric Cardiology, Primary Healthcare Centre "Zemun") ; Laius, Ott (Department of Post-authorisation Safety, State Agency of Medicines) ; Langner, Irene (Wissenschaftliches Institut der AOK) ; Mardare, Ileana (Faculty of Medicine, Public Health and Management Department, "Carol Davila" University of Medicine and Pharmacy Bucharest) ; Markovic-Pekovic, Vanda (Department of Social Pharmacy, Medical Faculty, University of Banja Luka) ; Magnusson, Einar (Department of Health Services, Ministry of Health) ; Melien, Oyvind (Norwegian Directorate for Health) ; Meshkov, Dmitry O. (Department of Health) ; Petrova, Guenka I. (Department of Social Pharmacy and Pharmacoeconomics, Faculty of Pharmacy, Medical University of Sofia) ; Selke, Gisbert (Wissenschaftliches Institut der AOK) ; Sermet, Catherine (Institut de Recherche et Documentation en Economie de la Santé (IRDES)) ; Simoens, Steven (KU Leuven Department of Pharmaceutical and Pharmacological Sciences) ; Schuurman, Ad (National Health Care Institute (ZIN)) ; Ramos, Ricardo (Health Technology Assessment, Pricing and Reimbursement Department, Central Administration of the Health System, National Authority of Medicines and Health Products (I.P., INFARMED)) ; Rodrigues, Jorge (Health Technology Assessment, Pricing and Reimbursement Department, Central Administration of the Health System, National Authority of Medicines and Health Products (I.P., INFARMED)) ; Zara, Corinne (Servei Català de la Salut) ; Zebedin-Brandl, Eva (Main Association of Austrian Social Insurance Institutions. Department of Pharmaceutical Affairs) ; Haycox, Alan (Health Economics Centre, University of Liverpool Management School) ; Universitat Autònoma de Barcelona
Medicines receiving a conditional marketing authorization through Medicines Adaptive Pathways to Patients (MAPPs) will be a challenge for payers. The "introduction" of MAPPs is already seen by the European Medicines Agency (EMA) as a fait accompli, with payers not consulted or involved. [...]
2017 - 10.3389/fphar.2017.00497
Frontiers in Pharmacology, Vol. 8 (august 2017)  
Registre complet - Creative Commons
2.
11 p, 1.1 MB Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs / Godman, Brian (University of Strathclyde) ; Malmström, Rickard E. (Karolinska University Hospital and Karolinska Institutet (Suècia)) ; Diogène Fadini, Eduard (Hospital Universitari Vall d'Hebron) ; Jayathissa, Sisira (Hutt Valley DHB. Department of Medicine) ; McTaggart, Stuart (NHS National Services Scotland) ; Cars, Thomas (Uppsala University. Department of Medical Sciences) ; Alvarez-Madrazo, Samantha (University of Strathclyde) ; Baumgärtel, Christoph (Austrian Medicines and Medical Devices Agency) ; Brzezinska, Anna (Agency for Health Technology Assessment) ; Bucsics, Anna (Hauptverband der Österreichischen Sozialversicherungsträger) ; Campbell, Stephen (University of Manchester. Centre for Primary Care) ; Eriksson, Irene (Stockholm County Council. Department of Healthcare Development) ; Finlayson, Alexander (University of Oxford. Green Templeton College) ; Fürst, Jurij (Health Insurance Institute) ; Garuoliene, Kristina (National Health Insurance Fund) ; Gutiérrez-Ibarluzea, Iñaki (Osasun Saila. Ezagutu Osteba arloa) ; Hviding, Krystyna (Norwegian Medicines Agency) ; Herholz, Harald (Kassenärztliche Vereinigung Hessen) ; Joppi, Roberta (Azienda Sanitaria Locale of Verona. Pharmaceutical Drug Department) ; Kalaba, Marija (Republic Institute for Health. Department of Medicines and Pharmacoeconomics) ; Laius, Ott (State Agency of Medicines) ; Malinowska, Kamila (National Health Fund. Drug Management Department) ; Pedersen, Hanne B. (Division of Health Systems and Public Health, Health Technologies and Pharmaceuticals, WHO Regional Office for Europe) ; Markovic-Pekovic, Vanda (Ministry of Health and Social Welfare) ; Piessnegger, Jutta (Hauptverband der Österreichischen Sozialversicherungsträger) ; Selke, Gisbert (Wissenschaftliches Institut der AOK (WidO)) ; Sermet, Catherine (IRDES) ; Spillane, Susan (Trinity College. Department of Pharmacology and Therapeutics) ; Tomek, Dominik (Slovak Medical University. Faculty of Pharmacy) ; Vončina, Luka (Ministry of Health) ; Vlahović-Palčevski, Vera (University Hospital Rijeka. Unit for Clinical Pharmacology) ; Wale, Janet (Independent Consumer Advocate, VIC) ; Wladysiuk, Magdalena (HTA Consulting) ; van Woerkom, Menno (Dutch Institute for Rational Use of Medicine) ; Zara, Corinne (Institut Català de la Salut) ; Gustafsson, Lars L. (Karolinska University Hospital and Karolinska Institutet (Suècia)) ; Universitat Autònoma de Barcelona
Background : There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there are effectiveness, safety and/or budget concerns. Dabigatran, a new oral anticoagulant for the prevention of stroke in patients with non-valvular atrial fibrillation (AF), exemplifies this issue. [...]
2014 - 10.3389/fphar.2014.00109
Frontiers in Pharmacology, Vol. 5 (june 2014)  
Registre complet - Creative Commons

Vegeu també: autors amb noms similars
1 Eriksson, I.
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem